VEGFA and diabetic macular edema: <h4>Purpose</h4>To evaluate the safety, tolerability, and effectiveness of the Everads Injector, a novel suprachoroidal drug delivery device, for administration of triamcinolone acetonide (TA) in patients with diabetic macular edema (DME).<h4>Design</h4>A prospective, open-label pilot study.<h4>Subjects</h4>Ten adult patients (10 eyes) with center-involved DME and inadequate response to prior anti-VEGF therapy.<h4>Methods</h4>Each participant received a single suprachoroidal injection of 4 mg of TA in 100 μL using the injector.